Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells $961,500.00 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 38,460 shares of Tango Therapeutics stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $25.00, for a total value of $961,500.00. Following the completion of the sale, the insider owned 112,622 shares in the company, valued at $2,815,550. This represents a 25.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Adam Crystal also recently made the following trade(s):

• On Wednesday, April 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $21.20, for a total value of $572,400.00.
• On Wednesday, March 25th, Adam Crystal sold 12,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $20.11, for a total value of $241,320.00.
• On Thursday, March 5th, Adam Crystal sold 20,251 shares of Tango Therapeutics stock. The shares were sold at an average price of $15.00, for a total value of $303,765.00.
• On Wednesday, February 25th, Adam Crystal sold 54,345 shares of Tango Therapeutics stock. The stock was sold at an average price of $12.77, for a total value of $693,985.65.
• On Tuesday, February 3rd, Adam Crystal sold 18,452 shares of Tango Therapeutics stock. The stock was sold at an average price of $12.26, for a total value of $226,221.52.

Tango Therapeutics Price Performance

TNGX opened at $26.64 on Friday. Tango Therapeutics, Inc. has a 12 month low of $1.03 and a 12 month high of $26.81. The stock has a market capitalization of $3.80 billion, a price-to-earnings ratio of -30.62 and a beta of 1.31. The business has a fifty day moving average price of $17.22 and a 200 day moving average price of $12.19.

Tango Therapeutics (NASDAQ:TNGX) last released its earnings results on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 50.30% and a negative net margin of 151.15%. On average, research analysts anticipate that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current year.

Institutional Trading of Tango Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Farallon Capital Management LLC lifted its holdings in shares of Tango Therapeutics by 21.4% in the 4th quarter. Farallon Capital Management LLC now owns 13,061,411 shares of the company’s stock valued at $115,724,000 after purchasing an additional 2,304,411 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Tango Therapeutics by 322.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 10,607,924 shares of the company’s stock valued at $93,986,000 after purchasing an additional 8,096,924 shares during the last quarter. Siren L.L.C. lifted its holdings in shares of Tango Therapeutics by 38.8% in the 4th quarter. Siren L.L.C. now owns 8,165,374 shares of the company’s stock valued at $72,345,000 after purchasing an additional 2,282,186 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Tango Therapeutics by 33.6% in the 4th quarter. Vanguard Group Inc. now owns 6,750,977 shares of the company’s stock valued at $59,814,000 after purchasing an additional 1,698,974 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Tango Therapeutics by 84.8% in the 4th quarter. State Street Corp now owns 6,218,567 shares of the company’s stock valued at $55,097,000 after purchasing an additional 2,853,362 shares during the last quarter. 78.99% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on TNGX. Jefferies Financial Group reaffirmed a “buy” rating and set a $18.00 price objective on shares of Tango Therapeutics in a research report on Thursday, March 5th. Wall Street Zen cut Tango Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Piper Sandler upped their price objective on Tango Therapeutics from $11.00 to $14.00 and gave the stock an “overweight” rating in a research report on Friday, January 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tango Therapeutics in a research report on Wednesday, January 21st. Finally, Stifel Nicolaus upped their price objective on Tango Therapeutics from $15.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.67.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.